March 21, 2023
3 min watch
Save
VIDEO: Rucaparib shows ‘trend towards improvement’ in TRITON3 trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Shilpa Gupta, MD, Director of the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute, discusses data from the TRITON3 trial presented at ASCO Genitourinary Cancers Symposium.
Gupta goes in-depth on the data from the trial, which studied rucaparib (Rubraca, Clovis Oncology) vs. physicians’ choice in patients with metastatic castration-resistant prostate cancer, and BRCA and ATM alterations, who had been exposed to an androgen-receptor-targeted agent.
“There was a trend towards improvement for rucaparib versus docetaxel or abiraterone and enzalutamide,” Dorff said.
Reference:
- Bryce A, et al. A study of rucaparib versus physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer and homologous recombination gene deficiency (TRITON3). Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gupta reports consulting for AVEO, EMD Serono, Gilead Sciences, Guardant Health, Loxo/Lilly, Merck and Pfizer.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.